NSI N.V. 16.380 € (-1,56 %) 
SHELL PLC 38.210 € (+0,79 %) 
CAPITAL B 0.507 € (+6,13 %) ATLAND 33.600 € (+0,30 %) GENFIT 14.060 € (+3,69 %) RELX 28.900 € (-2,69 %) ABIONYX PHARMA 1.864 € (+1,19 %) TKH GROUP 42.980 € (+1,27 %) CORBION 19.410 € (-1,87 %) MAISONS DU MONDE 0.188 € (-2,19 %) LEGRAND 137.250 € (+1,59 %) CREDIT AGRICOLE 18.105 € (+0,98 %) TIKEHAU CAPITAL 17.360 € (-2,03 %) CARBIOS 6.800 € (+23,41 %) 
ARCELORMITTAL SA 57.860 € (-0,65 %) ABN AMRO BANK N.V. 38.190 € (+2,00 %) PROSUS 38.495 € (-3,70 %) 
DSM FIRMENICH AG 83.980 € (-2,12 %) WOLTERS KLUWER 60.000 € (-2,31 %) PLANISWARE 20.000 € (-4,08 %) ALTEN 55.300 € (-2,12 %) BNP PARIBAS ACT.A 105.160 € (+1,80 %) 
THEON INTERNAT 32.980 € (+2,93 %) SEMCO TECHNOLOGIES 43.200 € (+4,10 %) KAUFMAN ET BROAD 26.150 € (+1,16 %) BILENDI 15.320 € (+2,68 %) WORLDLINE 10.160 € (+2,77 %) 
X-FAB 7.450 € (+7,74 %) 
AEGON 8.020 € (+0,35 %) ATOS GROUP 28.620 € (-5,23 %) PEUGEOT INVEST 56.100 € (+1,08 %) ASML HOLDING 1 593.400 € (+4,77 %) AUBAY 53.000 € (-2,03 %) IMCD 87.960 € (-0,43 %) UNILEVER 53.440 € (-2,21 %) SIRIUS MEDIA 0.640 € (-3,00 %) BUREAU VERITAS 27.060 € (-1,53 %) VICAT 60.800 € (-0,16 %) AKZO NOBEL 57.160 € (-0,45 %) INPOST 15.500 € (+0,26 %) L'OREAL 378.750 € (-0,43 %) BENETEAU 6.100 € (-0,97 %) UMG 18.500 € (+0,27 %) ORANGE 16.185 € (-1,52 %) WENDEL 80.050 € (-0,87 %) STMICROELECTRONICS 57.250 € (+4,26 %) ARCADIS 34.380 € (-0,87 %) BAM GROEP KON 11.670 € (+2,01 %) JCDECAUX 21.860 € (-1,44 %) LAKEFRONT BIOTHER. 25.640 € (-0,23 %) AIR LIQUIDE 176.520 € (-0,66 %) AXA 44.790 € (+0,07 %) BASIC-FIT 30.680 € (-0,78 %) CARREFOUR 16.545 € (-1,16 %) HEINEKEN 76.920 € (-0,44 %) HEXAOM 27.200 € (-2,86 %) KPN KON 4.247 € (-1,14 %) SLIGRO FOOD GROUP 11.520 € (-3,52 %) GETLINK SE 18.790 € (+0,05 %) MAUNA KEA TECH 0.170 € (+6,25 %) |
16/07/2026 22:10
DBV Technologies Announces the Filing of its 2026 Half-Year Report ? Conditions for Accessing or Consulting the ReportDBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the ReportDBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the semester ended June 30, 2026, of its Half-Year Report with the French market authority, “Autorité des Marchés Financiers” (“AMF”). The 2026 Half-Year Report can be consulted or downloaded from the Company’s website (www.dbv-technologies.com) in the section Investors/Financial Information, and on the AMF website (www.amf-france.org), in French only. About DBV TechnologiesDBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® Peanut Patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of people with food allergies. The Company’s food allergy programs include ongoing clinical trials of VIASKIN® Peanut Patch in toddlers (1 through 3 years of age) and children (4 through 7 years of age) with peanut allergy. DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). Châtillon, France, July 16, 2026 For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn. VIASKIN is a registered trademark of DBV Technologies. Investor Contact Media Contact Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière